GlassScriptPhysician profile
Alan B Fishman
NPI 1346290806
$958.01
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2021: $16.64.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $350.17 | 2019 | |
| Janssen Biotech, INC. | $128.37 | 2019 | |
| Pfizer INC. | $123.66 | 2019 | |
| Amgen INC. | $96.37 | 2019 | |
| Lilly USA, LLC | $74.81 | 2019 | |
| Celgene Corporation | $51.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.82 | 2019 | |
| Shire North American Group INC | $18.78 | 2019 | |
| Baxter Healthcare | $16.64 | 2021 | |
| Corcept Therapeutics | $15.31 | 2019 | |
| Sanofi Pasteur INC. | $14.36 | 2019 | |
| Medexus Pharma, INC. | $13.33 | 2019 | |
| Glaxosmithkline, LLC. | $12.15 | 2019 | |
| Merck Sharp & Dohme LLC | $11.86 | 2019 | |
| Vivus LLC | $11.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Fishman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.